Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Castle Biosciences CEO Derek Maetzold executed sales of common stock on March 20 and 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Derek Maetzold, the President and CEO of Castle Biosciences, sold shares of common stock on March 20 and March 21, 2024.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2023.
- On March 20, 2024, a total of 4,967 shares were sold at a price of $20.27 per share.
- On March 21, 2024, a total of 194 shares were sold at a price of $20.70 per share.
- The sales were made both directly and indirectly through various trusts for which Maetzold serves as trustee or has a beneficial interest.
- Following the reported transactions, Maetzold directly owns 69,733 shares of common stock.
- Maetzold also indirectly owns shares through The Maetzold Descendants 2020 Trust (88,542 shares), Derek Maetzold 2020 Irrevocable Trust (77,439 shares), The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk (10,457 shares), The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold (10,455 shares), The Maetzold 2018 Remainder Trust FBO John Derek Maetzold (10,455 shares), The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold (10,455 shares), and DJM Grantor Retained Annuity Trust No. 5 (149,000 shares).
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions.
Industry Context
Insider selling can sometimes be viewed negatively by the market, but sales under a pre-arranged 10b5-1 plan are generally viewed as less concerning since they are planned in advance and not based on current insider information. It is common for executives to use these plans for diversification or liquidity purposes.
Stakeholder Impact
- Shareholders may react to the news of insider selling, although the pre-planned nature of the sales may mitigate concerns.
Key Dates
| Date | Description |
|---|---|
| 12/05/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 03/20/2024 | Date of first stock sale |
| 03/21/2024 | Date of second stock sale |
| 03/22/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.